New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia
Since the introduction of new anthracycline derivatives and anthrachi none analogues a few years ago, aclacinomycin A (Aclarubicin) has become an established agent for the treatment of hematologic malig nancies. A special symposium was therefore held during the congress of the German Society of He...
| Other Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Berlin, Heidelberg
Springer Berlin Heidelberg
1990, 1990
|
| Edition: | 1st ed. 1990 |
| Subjects: | |
| Online Access: | |
| Collection: | Springer Book Archives -2004 - Collection details see MPG.ReNa |
Table of Contents:
- Aclarubicin in Single Agent and Combined Chemotherapy of Adult Acute Myeloid Leukemia
- Low-Dose Aclacinomycin and Intermediate-Dose Cytosine - Arabinoside in Relapsed and Refractory Acute Myelogenous Leukemia
- Aclarubicin Plus Cytosine Arabinoside Versus Daunorubicin Plus Cytosine Arabinoside in De Novo Acute Myelocytic Leukemia: A Danish National Trial
- Fractionated Aclacinomycin in Combination with Cytosine Arabinoside and Etoposide for Remission Induction in Adult Acute Myeloid Leukemia
- Aclarubicin in the Treatment of Refractory Acute Leukemias
- Aclacinomycin A/Etoposide Combination Therapy for Advanced Relapsed Acute Myeloid Leukemia: Results of a Pilot Study of the Arbeitsgemeinschaft Internistische Onkologie
- Low-Dose Aclacinomycin A in Myelodysplastic Syndromes and Subsequent Acute Myelogenous Leukemia: A Phase II Study